[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
January 1964

Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study

Author Affiliations

Lawton, Okla
From the Wilmer Ophthalmological Institute of The Johns Hopkins Hospital, Baltimore 5, Md.

Arch Ophthalmol. 1964;71(1):58-62. doi:10.1001/archopht.1964.00970010074010

Introduction  The treatment of toxoplasmic retinochoroiditis has been the subject of numerous investigations over the past ten years. Therapeutic regimes seem to fall into four general groups: (1) watchful waiting, (2) corticosteroids, (3) pyrimethamine (Daraprim) and sulfonamides, with or without corticosteroids, and (4) antimicrobial agents such as spiramycin, chlortetracycline (Aureomycin), chloramphenicol (Chloromycetin), etc. Since the earliest studies of Sabin and Warner25 in 1942, in which the therapeutic effectiveness of sulfonamides in toxoplasmosis of mice and rabbits was demonstrated, extensive investigations have been made to find a more specific therapeutic agent effective against this organism.In 1952, Eyles and Coleman6 initiated the first systematic survey of a number of compounds for antitoxoplasmic activity. These included the broad spectrum antibiotics, such as chloramphenicol, tetracyclines, neomycin, etc. The antitoxoplasmic activity of these compounds was slight and then only when used in extremely high doses.In March of 1952, these authors reported